SK-OV-3, a serous ovarian cancer cell line, has been used to study the effects of Ruxolitinib, a JAK1/2 inhibitor, in combination with chemotherapeutic agents. The gene discussed is JAK1; the disease is ovarian serous adenocarcinoma.